ID
13827
Description
This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination. NCT01571583
Keywords
Versions (1)
- 3/9/16 3/9/16 -
Copyright Holder
CC BY-NC 3.0
Uploaded on
March 9, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
VX-950HPC3006 NCT01571583 Date of visit
VX-950HPC3006 Date of visit
- StudyEvent: ODM
Similar models
VX-950HPC3006 Date of visit
- StudyEvent: ODM
C1880274 (UMLS CUI [1,2])